ReviewFrontiers in pharmacology2016
Anti-Hypertensive Herbs and Their Mechanisms of Action: Part II.
Review in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Multitarget Pharmacological Mechanisms and Safety Profiles of Six Ethnobotanically Prioritized Indonesian Medicinal Plants for Cardiometabolic Disorders: A Systematic Review.Drug design, development and therapy · 2026Pooled it
- Safety classification of herbal medicine use among hypertensive patients: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Antihypertensive Indigenous Lebanese Plants: Ethnopharmacology and a Clinical Trial.Biomolecules · 2019Trial
- 7-O-methylpunctatin is a potential inhibitor of human arachidonate 5-lipoxygenase: molecular and structural insights into anti-atherosclerosis therapeutics.Molecular diversity · 2026Article
- Medicinal plants administered to control hypertension in Ethiopia: ethnomedicine, pharmacology, nutraceutical, phytochemistry, toxicology, and policy perspectives.Frontiers in cardiovascular medicine · 2025Review
- Use of Herbal Drugs in Cardiovascular Disease- A Review.Current cardiology reviews · 2025Review
- The pharmaco-epigenetics of hypertension: a focus on microRNA.Molecular and cellular biochemistry · 2024Review
- The role of Kolaviron, a bioflavonoid fromHeliyon · 2024Article
- The Potential of Natural Products in the Management of Cardiovascular Disease.Current pharmaceutical design · 2024Review
- Elucidating the chemical profile and biological studies ofFrontiers in pharmacology · 2024Article
- Cardioprotective effect ofFrontiers in pharmacology · 2023Article
- Changes in Pharmacokinetics and Pharmacodynamics of Losartan in Experimental Diseased Rats Treated withPharmaceuticals (Basel, Switzerland) · 2022Article
- Article
- The effect ofFrontiers in pharmacology · 2022Article
- Article
- Biomarkers of Oxidative Stress Tethered to Cardiovascular Diseases.Oxidative medicine and cellular longevity · 2022Review
- Vasorelaxant Activities and its Underlying Mechanisms of Magnolia Volatile Oil on Rat Thoracic Aorta Based on Network Pharmacology.Frontiers in pharmacology · 2022Article
- Medicinal Plants in the Treatment of Hypertension: A Review.Advanced pharmaceutical bulletin · 2021Review
- Ayurveda and Epigenetics.Medicina (Kaunas, Lithuania) · 2020Review
- Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional medicine has a history extending back to thousands of years, and during the intervening time, man has identified the healing properties of a very broad range of plants. Globally, the use of herbal therapies to treat and manage cardiovascular disease (CVD) is on the rise. This is the second part of our comprehensive review where we discuss the mechanisms of plants and herbs used for the treatment and management of high blood pressure. Similar to the first part, PubMed and ScienceDirect databases were utilized, and the following keywords and phrases were used as inclusion criteria: hypertension, high blood pressure, herbal medicine, complementary and alternative medicine, endothelial cells, nitric oxide (NO), vascular smooth muscle cell (VSMC) proliferation, hydrogen sulfide, nuclear factor kappa-B (NF-κB), oxidative stress, and epigenetics/epigenomics. Each of the aforementioned keywords was co-joined with plant or herb in question, and where possible with its constituent molecule(s). This part deals in particular with plants that are used, albeit less frequently, for the treatment and management of hypertension. We then discuss the interplay between herbs/prescription drugs and herbs/epigenetics in the context of this disease. The review then concludes with a recommendation for more rigorous, well-developed clinical trials to concretely determine the beneficial impact of herbs and plants on hypertension and a disease-free living.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.